English
简体中文
Total: £ 56.28
Published Date: 2025-06-18 | Pages: 158 | Tables: 160 | Pharma & Healthcare
In 2024, the global market size of Chemotherapy Induced Peripheral Neuropathy Treatment was estimated to be worth US$ 1895 million and is forecast to reach approximately US$ 2907 million by 2031 with a CAGR of 6.4% during the forecast period 2025-2031.
CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.
There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.
Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.
The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Chemotherapy Induced Peripheral Neuropathy Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chemotherapy Induced Peripheral Neuropathy Treatment.
The Chemotherapy Induced Peripheral Neuropathy Treatment market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Chemotherapy Induced Peripheral Neuropathy Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and regions.
By Company
Aptinyx Inc
Asahi Kasei Pharma Corp
Regenacy Pharmaceuticals
MAKScientific LLC
Metys Pharmaceuticals AG
Nemus Bioscience Inc
PledPharma
Sova Pharmaceuticals Inc
DermaXon LLC
Kineta Inc
Krenitsky Pharmaceuticals Inc
PeriphaGen
Apexian Pharma
WinSanTor
Segment by Type
Calcium Channel α2-delta Ligands
Antidepressants
Opioids
Others
Segment by Application
Platinum Agents
Taxanes
Vinca Alkaloids
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, price, gross margin, sales by region, by Type, by Application, and recent development, etc.
Chapter 5: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: North America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: APAC by Type, by Application and by country, sales, and revenue for each segment.
Chapter 9: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 10: Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Middle East and Africa by Type, by Application and by country, sales, and revenue for each segment.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: Research Findings and Conclusion.
Research Methodology
The research methodology employed has been subjected by numerous procedures in order to guarantee the quality and accuracy of the data contained within the reports. The analysts are employed full-time and received more than six months training to satisfy the standard of our company. Our methodology can be divided into five stages:
★Stage 1 SECONDARY RESEARCH
The research team first collaborates with magazines, trade associations and administrative departments in the research field. The information provided by our internal documentation service is helpful for our further research. Our team has a wealth of experience and knowledge, and can effectively extract accurate information from existing resources.
★Stage 2 PRIMARY RESEARCH:INTERVIEWS WITH TRADE SOURCES
After the first stage, the research team conducts a large number of face-to-face or telephone interviews with representative companies working in the research field. Analysts are trying to have an opportunity to talk to leading companies and small companies in the field. Upstream suppliers, manufacturers, distributors, importers, installers, wholesalers and consumers were included in the interview. The data collected during the interview were then carefully examined and compared with the secondary study.
★Stage 3 ANALYSIS OF THE GATHERED DATA
The analysis team examines and synthesizes the data collected in the first two stages. In order to validate the data, a second round of interviews can be conducted.
★Stage 4 QUANTITATIVE DATA
The quantitative data such as market estimates, production and capacity of manufacturer, market forecasts and investment feasibility is provided by our company. The data is based on the estimates obtained during stage 3.
★Stage 5 QUALITY CONTROL
Before publishing, each report undergoes a rigorous review and editing process, which is done by the experience management team to ensure the reliability of the published data. Every analyst on the research team receives support and continuous training as part of our internal quality process.
1 Study Coverage
1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Introduction
1.2 Market by Type
1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (2020 VS 2024 VS 2031)
1.2.2 Calcium Channel α2-delta Ligands
1.2.3 Antidepressants
1.2.4 Opioids
1.2.5 Others
1.3 Market by Application
1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application (2020 VS 2024 VS 2031)
1.3.2 Platinum Agents
1.3.3 Taxanes
1.3.4 Vinca Alkaloids
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Estimates and Forecasts
2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2020-2031
2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2020-2031
2.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region: 2024 Versus 2031
2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2020-2031)
2.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2020-2025
2.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2026-2031)
2.3.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2031)
2.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Estimates and Projections by Region (2026-2031)
2.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2020-2025
2.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2026-2031)
2.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2020-2031)
3 Market Segments
3.1 Breakdown Data by Type
3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2031)
3.1.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2020-2031)
3.1.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2031)
3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2020-2031)
3.1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2020-2031)
3.1.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2020-2031)
3.1.3 Chemotherapy Induced Peripheral Neuropathy Treatment Average Selling Price (ASP) by Type (2020-2031)
3.2 Breakdown Data by Application
3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2031)
3.2.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2020-2031)
3.2.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2031)
3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2020-2031)
3.2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2020-2031)
3.2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2020-2031)
3.2.3 Chemotherapy Induced Peripheral Neuropathy Treatment Average Selling Price (ASP) by Application (2020-2031)
3.3 by Type and by Application Crossing Analysis
3.3.1 Calcium Channel α2-delta Ligands of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application
3.3.2 Antidepressants of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application
3.3.3 Opioids of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application
3.3.4 Others of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application
4 Global Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturers
4.1 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers by Sales (2020-2025)
4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturer (2020-2025)
4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturer (2020-2025)
4.2 Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers by Revenue (2020-2025)
4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturer (2020-2025)
4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturer (2020-2025)
4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturer (2020-2025)
4.4 Competitive Landscape
4.4.1 Key Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Covered: Ranking by Revenue
4.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Concentration Ratio (CR5 and HHI) & (2020-2025)
4.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.5 Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturing Base Distribution, Product Type
4.5.1 Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Manufacturing Base Distribution, Headquarters
4.5.2 Date of International Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
4.5.3 Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type and Application
4.5.4 Calcium Channel α2-delta Ligands Market Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturer
4.5.5 Antidepressants Market Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturer
4.5.6 Opioids Market Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturer
4.5.7 Others Market Sales of Chemotherapy Induced Peripheral Neuropathy Treatment by Manufacturer
4.6 Manufacturers Mergers & Acquisitions, Expansion Plans
5 Company Profiles
5.1 Aptinyx Inc
5.1.1 Aptinyx Inc Company Information
5.1.2 Aptinyx Inc Description, Business Overview
5.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.1.5 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.1.6 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.1.7 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.1.8 Aptinyx Inc Recent Developments
5.2 Asahi Kasei Pharma Corp
5.2.1 Asahi Kasei Pharma Corp Company Information
5.2.2 Asahi Kasei Pharma Corp Description, Business Overview
5.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.2.5 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.2.6 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.2.7 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.2.8 Asahi Kasei Pharma Corp Recent Developments
5.3 Regenacy Pharmaceuticals
5.3.1 Regenacy Pharmaceuticals Company Information
5.3.2 Regenacy Pharmaceuticals Description, Business Overview
5.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.3.5 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.3.6 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.3.7 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.3.8 Regenacy Pharmaceuticals Recent Developments
5.4 MAKScientific LLC
5.4.1 MAKScientific LLC Company Information
5.4.2 MAKScientific LLC Description, Business Overview
5.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.4.5 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.4.6 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.4.7 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.4.8 MAKScientific LLC Recent Developments
5.5 Metys Pharmaceuticals AG
5.5.1 Metys Pharmaceuticals AG Company Information
5.5.2 Metys Pharmaceuticals AG Description, Business Overview
5.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.5.5 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.5.6 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.5.7 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.5.8 Metys Pharmaceuticals AG Recent Developments
5.6 Nemus Bioscience Inc
5.6.1 Nemus Bioscience Inc Company Information
5.6.2 Nemus Bioscience Inc Description, Business Overview
5.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.6.5 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.6.6 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.6.7 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.6.8 Nemus Bioscience Inc Recent Developments
5.7 PledPharma
5.7.1 PledPharma Company Information
5.7.2 PledPharma Description, Business Overview
5.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.7.5 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.7.6 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.7.7 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.7.8 PledPharma Recent Developments
5.8 Sova Pharmaceuticals Inc
5.8.1 Sova Pharmaceuticals Inc Company Information
5.8.2 Sova Pharmaceuticals Inc Description, Business Overview
5.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.8.5 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.8.6 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.8.7 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.8.8 Sova Pharmaceuticals Inc Recent Developments
5.9 DermaXon LLC
5.9.1 DermaXon LLC Company Information
5.9.2 DermaXon LLC Description, Business Overview
5.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.9.5 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.9.6 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.9.7 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.9.8 DermaXon LLC Recent Developments
5.10 Kineta Inc
5.10.1 Kineta Inc Company Information
5.10.2 Kineta Inc Description, Business Overview
5.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.10.5 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.10.6 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.10.7 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.10.8 Kineta Inc Recent Developments
5.11 Krenitsky Pharmaceuticals Inc
5.11.1 Krenitsky Pharmaceuticals Inc Company Information
5.11.2 Krenitsky Pharmaceuticals Inc Description, Business Overview
5.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.11.5 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.11.6 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.11.7 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.11.8 Krenitsky Pharmaceuticals Inc Recent Developments
5.12 PeriphaGen
5.12.1 PeriphaGen Company Information
5.12.2 PeriphaGen Description, Business Overview
5.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.12.5 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.12.6 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.12.7 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.12.8 PeriphaGen Recent Developments
5.13 Apexian Pharma
5.13.1 Apexian Pharma Company Information
5.13.2 Apexian Pharma Description, Business Overview
5.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.13.5 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.13.6 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.13.7 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.13.8 Apexian Pharma Recent Developments
5.14 WinSanTor
5.14.1 WinSanTor Company Information
5.14.2 WinSanTor Description, Business Overview
5.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Products Offered
5.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Revenue and Gross Margin (2020-2025)
5.14.5 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Product in 2024
5.14.6 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application in 2024
5.14.7 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Geographic Area in 2024
5.14.8 WinSanTor Recent Developments
6 North America
6.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth 2020-2031
6.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
6.2.1 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2031)
6.2.2 North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2031)
6.3 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
6.4 North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
7 Asia-Pacific
7.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth 2020-2031
7.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Region
7.2.1 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2020-2031)
7.2.2 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2020-2031)
7.3 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
7.4 Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
8 Europe
8.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth 2020-2031
8.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
8.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2031)
8.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2031)
8.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
8.4 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
9 Latin America
9.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth 2020-2031
9.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
9.2.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2031)
9.2.2 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2031)
9.3 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
9.4 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
10 Middle East and Africa
10.1 Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size YoY Growth 2020-2031
10.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Market Facts & Figures by Country
10.2.1 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2031)
10.2.2 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2031)
10.3 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025)
10.4 Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025)
11 Supply Chain and Sales Channel analysis
11.1 Chemotherapy Induced Peripheral Neuropathy Treatment Supply Chain Analysis
11.2 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials and Upstream Suppliers
11.3 Chemotherapy Induced Peripheral Neuropathy Treatment Clients Analysis
11.4 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channel and Sales Model Analysis
11.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Distribution Channel Analysis: Indirect Sales VS Direct Sales
11.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distribution Channel Analysis: Online Sales VS Offline Sales
11.4.3 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
12 Chemotherapy Induced Peripheral Neuropathy Treatment Market Dynamics
12.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends
12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
12.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.1.1 Research Programs/Design
14.1.1.2 Market Size Estimation
14.1.1.3 Market Breakdown and Data Triangulation
14.1.2 Data Source
14.1.2.1 Secondary Sources
14.1.2.2 Primary Sources
14.2 Author Details
14.3 Disclaimer
List of Tables
Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
Table 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
Table 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Region (US$ Million): 2024 VS 2031
Table 4. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2020-2025) & (K Units)
Table 5. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Forecast by Region (2026-2031) & (K Units)
Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2020-2025) & (US$ Million)
Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Region (2026-2031) & (US$ Million)
Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2020-2025) & (K Units)
Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Type (2026-2031) & (K Units)
Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2020-2025) & (US$ Million)
Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Forecast by Type (2026-2031) & (US$ Million)
Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2020-2025) & (K Units)
Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Volume by Application (2026-2031) & (K Units)
Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2020-2025) & (US$ Million)
Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2026-2031) & (US$ Million)
Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturer (2020-2025) & (K Units)
Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturer (2020-2025)
Table 18. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturer (2020-2025) & (US$ Million)
Table 19. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturer (2020-2025)
Table 20. Key Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Price (2020-2025) & (US$/Unit)
Table 21. Ranking of Global Top Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers by Revenue (US$ Million) in 2024
Table 22. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI) & (2020-2025)
Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2024)
Table 24. Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Manufacturing Base Distribution and Headquarters
Table 25. Date of International Manufacturers Enter into Chemotherapy Induced Peripheral Neuropathy Treatment Market
Table 26. Manufacturers Chemotherapy Induced Peripheral Neuropathy Treatment Product Type and Application
Table 27. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 28. Aptinyx Inc Company Information
Table 29. Aptinyx Inc Description and Business Overview
Table 30. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 31. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 32. Aptinyx Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 33. Aptinyx Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 34. Aptinyx Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 35. Aptinyx Inc Recent Developments
Table 36. Asahi Kasei Pharma Corp Company Information
Table 37. Asahi Kasei Pharma Corp Description and Business Overview
Table 38. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 39. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 40. Asahi Kasei Pharma Corp Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 41. Asahi Kasei Pharma Corp Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 42. Asahi Kasei Pharma Corp Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 43. Asahi Kasei Pharma Corp Recent Developments
Table 44. Regenacy Pharmaceuticals Company Information
Table 45. Regenacy Pharmaceuticals Description and Business Overview
Table 46. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 47. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 48. Regenacy Pharmaceuticals Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 49. Regenacy Pharmaceuticals Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 50. Regenacy Pharmaceuticals Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 51. Regenacy Pharmaceuticals Recent Developments
Table 52. MAKScientific LLC Company Information
Table 53. MAKScientific LLC Description and Business Overview
Table 54. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 55. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 56. MAKScientific LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 57. MAKScientific LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 58. MAKScientific LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 59. MAKScientific LLC Recent Developments
Table 60. Metys Pharmaceuticals AG Company Information
Table 61. Metys Pharmaceuticals AG Description and Business Overview
Table 62. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 63. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 64. Metys Pharmaceuticals AG Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 65. Metys Pharmaceuticals AG Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 66. Metys Pharmaceuticals AG Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 67. Metys Pharmaceuticals AG Recent Developments
Table 68. Nemus Bioscience Inc Company Information
Table 69. Nemus Bioscience Inc Description and Business Overview
Table 70. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 71. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 72. Nemus Bioscience Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 73. Nemus Bioscience Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 74. Nemus Bioscience Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 75. Nemus Bioscience Inc Recent Developments
Table 76. PledPharma Company Information
Table 77. PledPharma Description and Business Overview
Table 78. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 79. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 80. PledPharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 81. PledPharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 82. PledPharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 83. PledPharma Recent Developments
Table 84. Sova Pharmaceuticals Inc Company Information
Table 85. Sova Pharmaceuticals Inc Description and Business Overview
Table 86. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 87. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 88. Sova Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 89. Sova Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 90. Sova Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 91. Sova Pharmaceuticals Inc Recent Developments
Table 92. DermaXon LLC Company Information
Table 93. DermaXon LLC Description and Business Overview
Table 94. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 95. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 96. DermaXon LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 97. DermaXon LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 98. DermaXon LLC Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 99. DermaXon LLC Recent Developments
Table 100. Kineta Inc Company Information
Table 101. Kineta Inc Description and Business Overview
Table 102. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 103. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 104. Kineta Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 105. Kineta Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 106. Kineta Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 107. Kineta Inc Recent Developments
Table 108. Krenitsky Pharmaceuticals Inc Company Information
Table 109. Krenitsky Pharmaceuticals Inc Description and Business Overview
Table 110. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 111. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 112. Krenitsky Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 113. Krenitsky Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 114. Krenitsky Pharmaceuticals Inc Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 115. Krenitsky Pharmaceuticals Inc Recent Developments
Table 116. PeriphaGen Company Information
Table 117. PeriphaGen Description and Business Overview
Table 118. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 119. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 120. PeriphaGen Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 121. PeriphaGen Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 122. PeriphaGen Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 123. PeriphaGen Recent Developments
Table 124. Apexian Pharma Company Information
Table 125. Apexian Pharma Description and Business Overview
Table 126. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 127. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 128. Apexian Pharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 129. Apexian Pharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 130. Apexian Pharma Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 131. Apexian Pharma Recent Developments
Table 132. WinSanTor Company Information
Table 133. WinSanTor Description and Business Overview
Table 134. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product
Table 135. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
Table 136. WinSanTor Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Product in 2024
Table 137. WinSanTor Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Application in 2024
Table 138. WinSanTor Sales Proportion of Chemotherapy Induced Peripheral Neuropathy Treatment by Geographic Area in 2024
Table 139. WinSanTor Recent Developments
Table 140. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2025) & (K Units)
Table 141. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2026-2031) & (K Units)
Table 142. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2025) & (US$ Million)
Table 143. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2026-2031) & (US$ Million)
Table 144. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 145. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 146. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2020-2025) & (K Units)
Table 147. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2026-2031) & (K Units)
Table 148. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2020-2025) & (US$ Million)
Table 149. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2026-2031) & (US$ Million)
Table 150. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 151. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 152. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2025) & (K Units)
Table 153. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2026-2031) & (K Units)
Table 154. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2025) & (US$ Million)
Table 155. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2026-2031) & (US$ Million)
Table 156. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 157. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 158. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2025) & (K Units)
Table 159. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2026-2031) & (K Units)
Table 160. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2025) & (US$ Million)
Table 161. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2026-2031) & (US$ Million)
Table 162. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 163. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 164. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2020-2025) & (K Units)
Table 165. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2026-2031) & (K Units)
Table 166. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2020-2025) & (US$ Million)
Table 167. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2026-2031) & (US$ Million)
Table 168. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2020-2025) & (K Units)
Table 169. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2020-2025) & (K Units)
Table 170. Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials, Industry Status and Trend
Table 171. Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials and Upstream Suppliers
Table 172. Chemotherapy Induced Peripheral Neuropathy Treatment Clients Status and Trend
Table 173. Chemotherapy Induced Peripheral Neuropathy Treatment Typical Clients
Table 174. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors
Table 175. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends
Table 176. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers
Table 177. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges
Table 178. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints
Table 179. Research Programs/Design for This Report
Table 180. Key Data Information from Secondary Sources
Table 181. Key Data Information from Primary Sources
Table 182. QYR Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture
Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type (US$ Million): 2020 VS 2024 VS 2031
Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type in 2024 & 2031
Figure 4. Calcium Channel α2-delta Ligands Product Picture
Figure 5. Antidepressants Product Picture
Figure 6. Opioids Product Picture
Figure 7. Others Product Picture
Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application (US$ Million): 2020 VS 2024 VS 2031
Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application in 2024 & 2031
Figure 10. Platinum Agents
Figure 11. Taxanes
Figure 12. Vinca Alkaloids
Figure 13. Others
Figure 14. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered
Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size 2020-2031 (US$ Million)
Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2020-2031 (K Units)
Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Region (2020-2031)
Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2020-2031)
Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Type (2020-2031)
Figure 21. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Type (2020-2031)
Figure 22. Chemotherapy Induced Peripheral Neuropathy Treatment Average Selling Price (ASP) by Type (2020-2025) & (US$/Unit)
Figure 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share Forecast by Application (2020-2031)
Figure 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share Forecast by Application (2020-2031)
Figure 25. Chemotherapy Induced Peripheral Neuropathy Treatment Average Selling Price (ASP) by Application (2020-2025) & (US$/Unit)
Figure 26. Calcium Channel α2-delta Ligands of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application, 2024 VS 2031
Figure 27. Antidepressants of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application, 2024 VS 2031
Figure 28. Opioids of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application, 2024 VS 2031
Figure 29. Others of Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application, 2024 VS 2031
Figure 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturer in 2024
Figure 31. Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
Figure 32. Calcium Channel α2-delta Ligands Market Sales Proportion by Manufacturer in 2024
Figure 33. Antidepressants Market Sales Proportion by Manufacturer in 2024
Figure 34. Opioids Market Sales Proportion by Manufacturer in 2024
Figure 35. Others Market Sales Proportion by Manufacturer in 2024
Figure 36. North America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2020-2031 (US$ Million)
Figure 37. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Figure 38. North America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Figure 39. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2020-2031 (US$ Million)
Figure 40. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2020-2031)
Figure 41. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2020-2031)
Figure 42. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Figure 43. Asia-Pacific Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Figure 44. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2020-2031 (US$ Million)
Figure 45. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2020-2031)
Figure 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2020-2031)
Figure 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Figure 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Figure 49. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2020-2031 (US$ Million)
Figure 50. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2020-2031)
Figure 51. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2020-2025)
Figure 52. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Figure 53. Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Figure 54. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Growth Rate 2020-2031 (US$ Million)
Figure 55. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Country (2020-2031)
Figure 56. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Country (2020-2031)
Figure 57. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2020-2025)
Figure 58. Middle East and Africa Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2020-2025)
Figure 59. Chemotherapy Induced Peripheral Neuropathy Treatment Supply Chain (Upstream and Downstream Market)
Figure 60. Global Production Market Share of Chemotherapy Induced Peripheral Neuropathy Treatment Raw Materials by Region in 2024
Figure 61. Chemotherapy Induced Peripheral Neuropathy Treatment Distribution Channels
Figure 62. Global Chemotherapy Induced Peripheral Neuropathy Treatment Percentage 2020-2031: Indirect Sales VS Direct Sales
Figure 63. Global Chemotherapy Induced Peripheral Neuropathy Treatment Percentage 2020-2031: Online Sales VS Offline Sales
Figure 64. Bottom-up and Top-down Approaches for This Report
Figure 65. Data Triangulation
Figure 66. Key Executives Interviewed
